An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
The partners also aim to expand their work to Latin America for the first time
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Under the agreement, Univar Solutions customers in Brazil and Mexico will have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Subscribe To Our Newsletter & Stay Updated
